Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035

View original at globenewswire.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • IV route accounts for 90% of ADC administration in 2024

    80% confidence

  • Asia-Pacific is the fastest growing ADC market region

    80% confidence

  • Generic/biosimilar ADCs are the fastest growing drug type segment

    80% confidence

  • Solid tumors represent the fastest growing therapeutic area for ADCs

    80% confidence

  • Hospital pharmacies and oncology centers represent 70% of ADC distribution in 2024

    80% confidence

  • Cytotoxic payloads represent 70% of ADC payload market share in 2024

    80% confidence

  • Global antitumor ADC drugs market will grow from $8.33B in 2026 to $24.75B in 2035 at 12.86% CAGR

    80% confidence

  • Branded ADC drugs represent 75% market share in 2024

    80% confidence

  • Hematologic cancers represent 35% of ADC therapeutic area market in 2024

    80% confidence

  • North America holds 55% revenue share of ADC market in 2024

    80% confidence

  • Cleavable linkers represent 60% of ADC linker market share in 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 — Source | Via News | ViaNews EU